Breaking News Instant updates and real-time market news.

MRK

Merck

$62.66

-0.14 (-0.22%)

, INCY

Incyte

$94.78

-0.91 (-0.95%)

07:57
10/07/16
10/07
07:57
10/07/16
07:57

Incyte to hold a pharmaceutical update conference call

Management discusses updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of Epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with Pembrolizumab (Keytruda), Merck's anti-PD-1 therapy, on a conference call to be held on October 7 at 8 am. Webcast Link

MRK

Merck

$62.66

-0.14 (-0.22%)

INCY

Incyte

$94.78

-0.91 (-0.95%)

  • 07

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.66

-0.14 (-0.22%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
INCY Incyte
$94.78

-0.91 (-0.95%)

09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$55.35

0.75 (1.37%)

, BK

BNY Mellon

$57.89

0.35 (0.61%)

20:25
01/17/18
01/17
20:25
01/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$55.35

0.75 (1.37%)

BK

BNY Mellon

$57.89

0.35 (0.61%)

BBT

BB&T

$53.28

0.2 (0.38%)

PPG

PPG

$114.50

-2.14 (-1.83%)

MTB

M&T Bank

$179.21

1.43 (0.80%)

KEY

KeyCorp

$21.26

-0.06 (-0.28%)

JBHT

J.B. Hunt

$120.65

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Mar

  • 10

    May

ARNA

Arena Pharmaceuticals

$34.36

0.48 (1.42%)

20:24
01/17/18
01/17
20:24
01/17/18
20:24
Initiation
Arena Pharmaceuticals initiated at Credit Suisse »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

20:12
01/17/18
01/17
20:12
01/17/18
20:12
Initiation
Rosehill Resources initiated at Northland »

Rosehill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Hess Corp. initiated at Macquarie »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

OXY

Occidental Petroleum

$75.86

0.59 (0.78%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Occidental Petroleum initiated at Macquarie »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

19:53
01/17/18
01/17
19:53
01/17/18
19:53
Downgrade
Juno Therapeutics rating change at Citi »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.89

-0.37 (-0.47%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Upgrade
Worldpay rating change at BMO Capital »

Worldpay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$18.51

0.63 (3.52%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Syndicate
Keane Group 13.3M share Secondary priced at $18.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

INTC

Intel

$44.39

1.25 (2.90%)

19:24
01/17/18
01/17
19:24
01/17/18
19:24
Hot Stocks
Intel says issued firmware updates for 90% of CPUs in past vie years »

Intel said it has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

TOSBF

Toshiba, also use TOSYY

, TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

19:11
01/17/18
01/17
19:11
01/17/18
19:11
Periodicals
Toshiba's Westinghouse to forgo bankruptcy, Reuters reports »

Westinghouse Electric…

TOSBF

Toshiba, also use TOSYY

TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

BAM

Brookfield

$43.10

0.42 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

, RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

19:02
01/17/18
01/17
19:02
01/17/18
19:02
Periodicals
Shell, BP each agree to purchase Libyan oil, Bloomberg reports »

Royal Dutch Shell (RDS.A)…

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

BP

BP

$42.88

0.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$179.10

2.91 (1.65%)

18:31
01/17/18
01/17
18:31
01/17/18
18:31
Hot Stocks
Trump says Apple investments 'huge win for American workers' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MPVD

Mountain Province Diamonds

$2.83

0.075 (2.73%)

18:22
01/17/18
01/17
18:22
01/17/18
18:22
Hot Stocks
Mountain Province Diamonds provides update on Gahcho Kue Mine exploration »

Mountain Province…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAC

Walter Investment

$0.76

0.0347 (4.81%)

18:17
01/17/18
01/17
18:17
01/17/18
18:17
Hot Stocks
Walter Investment prepackaged Chapter 11 plan approved by court »

Walter Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$140.72

2.75 (1.99%)

, KBSTY

Kobe Steel

18:10
01/17/18
01/17
18:10
01/17/18
18:10
Periodicals
Toyota not affected by Kobe Steel false data scandal, Nikkei reports »

Toyota (TM) said there…

TM

Toyota

$140.72

2.75 (1.99%)

KBSTY

Kobe Steel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

, BTC

Bitcoin

17:47
01/17/18
01/17
17:47
01/17/18
17:47
Hot Stocks
Cboe conducts first settlement of Cboe bitcoin futures »

Cboe Global Markets…

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

GWRE

Guidewire

$75.64

0.19 (0.25%)

17:46
01/17/18
01/17
17:46
01/17/18
17:46
Hot Stocks
Guidewire director sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

17:40
01/17/18
01/17
17:40
01/17/18
17:40
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple cash repatriation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

OBE

Obsidian Energy

$1.21

-0.03 (-2.42%)

17:36
01/17/18
01/17
17:36
01/17/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Obsidian Energy »

FrontFour reports 5.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SN

Sanchez Energy

$5.81

0.16 (2.83%)

17:33
01/17/18
01/17
17:33
01/17/18
17:33
Hot Stocks
Breaking Hot Stocks news story on Sanchez Energy »

Sanchez Energy sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NTDOY

Nintendo

$51.53

1.55 (3.10%)

17:32
01/17/18
01/17
17:32
01/17/18
17:32
Hot Stocks
Nintendo announces Nintendo Labo accessories for Switch consoles »

Nintendo introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PTC

PTC

$66.70

1.41 (2.16%)

, ESIO

Electro Scientific

$22.01

1.91 (9.50%)

17:28
01/17/18
01/17
17:28
01/17/18
17:28
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PTC…

PTC

PTC

$66.70

1.41 (2.16%)

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

NEOT

Neothetics

$1.92

0.0793 (4.31%)

PLXS

Plexus

$64.36

0.59 (0.93%)

AA

Alcoa

$56.99

0.75 (1.33%)

SLM

Sallie Mae

$11.49

0.02 (0.17%)

ARWR

Arrowhead

$5.72

0.12 (2.14%)

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

IIPR

Innovative Industrial Properties

$31.30

-2.49 (-7.37%)

ECC

Eagle Point Credit

$19.13

-0.39 (-2.00%)

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 07

    Feb

  • 26

    Feb

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

BTU

Peabody Energy

$40.00

0.42 (1.06%)

17:17
01/17/18
01/17
17:17
01/17/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Peabody Energy »

Discovery Capital reduces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

MLNX

Mellanox

$64.30

-0.45 (-0.69%)

17:12
01/17/18
01/17
17:12
01/17/18
17:12
Hot Stocks
Starboard to nominate nine directors for election at Mellanox »

Starboard Value, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

APHB

AmpliPhi

$1.12

0.03 (2.75%)

17:11
01/17/18
01/17
17:11
01/17/18
17:11
Syndicate
AmpliPhi requests withdrawal of registration statement »

AmpliPhi confirms that no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.